A Phase 3 interventional study of GSK1349572 (dolutegravir) and raltegravir in Infection, Human Immunodeficiency Virus I, sponsored by ViiV Healthcare. Completed at 101 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-09.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg once daily versus RAL 400mg twice daily over 48 weeks; non-inferiority will also be tested at Week 96. Both GSK1349572 and RAL will be given in combination with fixed-dose dual NRTI therapy (ABC/3TC or TDF/FTC). This study will be conducted in HIV-1 infected ART-naïve adult subjects.
ING113086 is a Phase 3 randomized, double-blind, double dummy, active-controlled, multicenter, study conducted in approximately 788 HIV-1 infected ART-naïve subjects. Subjects will be randomized 1:1 one of the following treatment arms:
GSK1349572 50 mg once daily (approximately 394 subjects) + fixed-dose dual NRTI therapy (either ABC/3TC or TDF/FTC)
OR
Analyses will be conducted at 48 weeks and 96 weeks. Subjects randomized to receive GSK1349572 and who successfully complete 96 weeks of treatment will continue to have access to GSK1349572 through the study until either it is locally available, as long as they continue to derive clinical benefit.
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 828 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
Drug: GSK1349572 (dolutegravir) · Other: GSK1349572 Placebo · Other: ABC/3TC · Other: TDF/FTC
raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily
Drug: raltegravir · Other: ABC/3TC · Other: TDF/FTC · Other: raltegravir Placebo
GSK1349572 50 mg taken once daily with or without food
raltegravir 400mg taken twice daily
GSK1349572 placebo taken once daily
Abacavir/Lamivudine background therapy once daily
Tenofovir/emtricitabine background therapy once daily
raltegravir placebo taken twice daily
Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 Copies (c)/Milliliter (mL) Through Week 48
Percentage of participants with plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) with \<50 c/mL was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) snapshot algorithm. The algorithm treats all participants without HIV-1 RNA data as non-responders, as well as participants who switch their concomitant Antiretroviral Therapy (ART) prior to Week 48 as follows: background ART substitutions not permitted per study; background ART substitutions permitted per study unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the subject was on-treatment. Intent-to-Treat Exposed (ITT-E) Population comprised all randomized participants who received at least one dose of study medication.
Time frame: Baseline up to Week 48
Number of Participants With Detectable HIV-1 Virus That Has Genotypic or Phenotypic Evidence of INI Resistance.
Number of participants with detectable virus that has genotypic or phenotypic evidence of Integrase Inhibitor (INI) resistance were assessed at Week 48 and Week 96. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the deoxyribonucleic acid (DNA) of the host cell.
Time frame: Week 48 and Week 96
Number of Participants With Plasma HIV-1 RNA <50 c/mL
The number of participants with plasma HIV-1 RNA level \<50 c/mL was assessed at Week 96.
Time frame: Week 96
Number of Participants With Plasma HIV-1 RNA <400 c/mL
The number of participants with plasma HIV-1 RNA level \<400 c/mL was assessed at Week 48 and Week 96.
Time frame: Week 48 and Week 96
Change From Baseline in Plasma HIV-1 RNA Over Time
Change from Baseline in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as the measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).
Time frame: Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96
Absolute Values in Plasma HIV-1 RNA Over Time
Absolute values in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).
Time frame: Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96
Change From Baseline in Cluster of Differentiation (CD)4+ Cell Counts Over Time
CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the participants disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start ART. Changes from Baseline in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).
Time frame: Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96
Absolute Values in CD4+ Cell Counts Over Time
CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy absolute values in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).
Time frame: Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96
Number of Participants With the Indicated Post-Baseline HIV-associated Conditions and Progression, Excluding Recurrences
Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline to a CDC CAT C event (EV); CDC CAT B at Baseline to a CDC CAT C EV; CDC CAT C at Baseline to a new CDC CAT C EV; or CDC CAT A, B, or C at Baseline to death.
Time frame: From Baseline until Week 96
Number of Participants With the Indicated Grade 1 to 4 Clinical Chemistry and Hematology Toxicities/Laboratory Adverse Events (AEs)
All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Safety Population: all participants who received at least one dose of investigational product
Time frame: From Baseline until Week 96
Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau [AUC(0-tau)] of DTG
AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. The predicted individual AUC(0-tau) were obtained from the final population PK model by an empirical Bayes estimation. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hours post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa. The Pharmacokinetic (PK) Concentration Population comprised of all participants who received DTG, had undergone PK sampling during the study, and provided evaluable DTG plasma concentration data.
Time frame: Week 4, Week 24, and Week 48
Maximum Plasma Concentration (Cmax) and Concentration at the End of a Dosing Interval (Ctau) of DTG
The maximum plasma concentration (Cmax) and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Week 48. The predicted individual Cmax and Ctau were obtained from the final population PK model by simulation of the concentration-time profiles. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hour post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa.
Time frame: Week 4, Week 24, and Week 48
This was a randomized, parallel group, non-inferiority study to demonstrate the antiviral activity of Dolutegravir. Participants were enrolled from 9 countries. Participants in Dolutegravir arm who completed 96 Weeks double-blind phase continued to receive Dolutegravir in open-label phase, until dolutegravir was locally available commercially.
| Milestone | DTG 50 mg Once a Day | RTG 400 mg BID | DTG 50 mg Once a Day (Open-label) |
|---|---|---|---|
| Started | 411 | 411 | 0 |
| Completed | 304 | 332 | 0 |
| Not completed | 107 | 79 | 0 |
| Withdrew: Adverse event | 12 | 7 | 0 |
| Withdrew: Lack of efficacy | 22 | 25 | 0 |
| Withdrew: Protocol violation | 18 | 16 | 0 |
| Withdrew: Met protocol-defined stopping criteria | 6 | 3 | 0 |
| Withdrew: Study closed/terminated | 6 | 4 | 0 |
| Withdrew: Lost to follow-up | 22 | 10 | 0 |
| Withdrew: Withdrawal by subject | 18 | 14 | 0 |
| Withdrew: Physician decision | 3 | 0 | 0 |
| Milestone | DTG 50 mg Once a Day | RTG 400 mg BID | DTG 50 mg Once a Day (Open-label) |
|---|---|---|---|
| Started | 0 | 0 | 338 |
| Completed | 0 | 0 | 294 |
| Not completed | 0 | 0 | 44 |
| Withdrew: Adverse event | 0 | 0 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 5 |
| Withdrew: Met protocol-defined stopping criteria | 0 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 15 |
| Withdrew: Withdrawal by subject | 0 | 0 | 8 |
| Withdrew: Physician decision | 0 | 0 | 3 |
Percentage of participants with plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) with \<50 c/mL was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) snapshot algorithm. The algorithm treats all participants without HIV-1 RNA data as non-responders, as well as participants who switch their concomitant Antiretroviral Therapy (ART) prior to Week 48 as follows: background ART substitutions not permitted per study; background ART substitutions permitted per study unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the subject was on-treatment. Intent-to-Treat Exposed (ITT-E) Population comprised all randomized participants who received at least one dose of study medication.
| Percentage of participants | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 Copies (c)/Milliliter (mL) Through Week 48 | 88 | 85 |
Number of participants with detectable virus that has genotypic or phenotypic evidence of Integrase Inhibitor (INI) resistance were assessed at Week 48 and Week 96. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the deoxyribonucleic acid (DNA) of the host cell.
| Participants | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Week 48, genotypic | 0 | 1 |
| Week 48, phenotypic | 1 | 2 |
| Week 96, genotypic | 0 | 1 |
| Week 96, phenotypic | 1 | 2 |
The number of participants with plasma HIV-1 RNA level \<50 c/mL was assessed at Week 96.
| Participants | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Number of Participants With Plasma HIV-1 RNA <50 c/mL | 332 | 314 |
The number of participants with plasma HIV-1 RNA level \<400 c/mL was assessed at Week 48 and Week 96.
| Participants | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Week 48 | 369 | 356 |
| Week 96 | 338 | 321 |
Change from Baseline in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as the measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).
| log10 c/mL | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Baseline n=411, 411 | 4.538 ± 0.7258 | 4.599 ± 0.7048 |
| Week 4, n=402, 406 | -2.817 ± 0.6198 | -2.801 ± 0.6041 |
| Week 8, n=397, 402 | -2.897 ± 0.6837 | -2.886 ± 0.6754 |
| Week 12, n=396, 395 | -2.908 ± 0.6863 | -2.918 ± 0.6834 |
| Week 16, n=395, 388 | -2.917 ± 0.6949 | -2.943 ± 0.6841 |
| Week 24, n=393, 390 | -2.896 ± 0.7889 | -2.933 ± 0.7398 |
| Week 32, n=386, 377 | -2.907 ± 0.7609 | -2.947 ± 0.7613 |
| Week 40, n=375, 358 | -2.920 ± 0.7219 | -2.946 ± 0.6700 |
| Week 48, n=374, 358 | -2.915 ± 0.7237 | -2.942 ± 0.6737 |
| Week 60, n=366, 355 | -2.912 ± 0.7344 | -2.937 ± 0.6685 |
| Week 72, n=361, 350 | -2.917 ± 0.7261 | -2.932 ± 0.6728 |
| Week 84, n=352, 338 | -2.932 ± 0.7073 | -2.916 ± 0.6646 |
| Week 96, n=342, 329 | -2.938 ± 0.7004 | -2.901 ± 0.7072 |
Absolute values in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).
| log10 c/mL | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Baseline n=411, 411 | 4.538 ± 0.7258 | 4.599 ± 0.7048 |
| Week 4, n=402, 406 | 1.718 ± 0.2593 | 1.800 ± 0.4095 |
| Week 8, n=397, 402 | 1.646 ± 0.2006 | 1.709 ± 0.3791 |
| Week 12, n=396, 395 | 1.626 ± 0.1323 | 1.672 ± 0.3125 |
| Week 16, n=395, 388 | 1.620 ± 0.1252 | 1.648 ± 0.2647 |
| Week 24, n=393, 390 | 1.643 ± 0.2950 | 1.655 ± 0.3476 |
| Week 32, n=386, 377 | 1.620 ± 0.1917 | 1.636 ± 0.2721 |
| Week 40, n=375, 358 | 1.603 ± 0.0821 | 1.601 ± 0.0784 |
| Week 48, n=374, 358 | 1.606 ± 0.0866 | 1.599 ± 0.0582 |
| Week 60, n=366, 355 | 1.605 ± 0.1134 | 1.599 ± 0.0560 |
| Week 72, n=361, 350 | 1.601 ± 0.0803 | 1.605 ± 0.0836 |
| Week 84, n=352, 338 | 1.607 ± 0.1337 | 1.614 ± 0.1279 |
| Week 96, n=342, 329 | 1.599 ± 0.830 | 1.630 ± 0.2515 |
CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the participants disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start ART. Changes from Baseline in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).
| Cells per cubic millimeter (cells/mm^3) | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Baseline n=411, 411 | 379.2 ± 178.32 | 374.3 ± 163.37 |
| Week 4, n=398, 403 | 93.3 ± 116.27 | 97.2 ± 129.35 |
| Week 8, n=398, 402 | 121.6 ± 127.97 | 126.6 ± 134.59 |
| Week 12, n=392, 397 | 130.7 ± 131.49 | 145.1 ± 144.08 |
| Week 16, n=394, 392 | 155.1 ± 137.23 | 173.0 ± 159.10 |
| Week 24, n=392, 389 | 199.3 ± 161.23 | 204.2 ± 162.28 |
| Week 32, n=384, 375 | 223.4 ± 165.30 | 241.3 ± 167.64 |
| Week 40, n=371, 357 | 224.1 ± 173.59 | 239.8 ± 173.33 |
| Week 48, n=374, 357 | 238.9 ± 171.81 | 257.5 ± 178.69 |
| Week 60, n=367, 355 | 247.8 ± 184.11 | 264.2 ± 188.63 |
| Week 72, n=360, 350 | 247.8 ± 168.37 | 278.6 ± 182.76 |
| Week 84, n=351, 338 | 281.3 ± 175.07 | 292.9 ± 199.42 |
| Week 96, n=343, 328 | 292.2 ± 195.70 | 286.2 ± 192.45 |
CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy absolute values in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).
| cells/mm^3 | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Baseline n=411, 411 | 379.2 ± 172.32 | 374.3 ± 163.37 |
| Week 4, n=398, 403 | 474.2 ± 199.06 | 471.8 ± 191.02 |
| Week 8, n=398, 402 | 502.3 ± 205.15 | 502.4 ± 187.99 |
| Week 12, n=392, 397 | 513.3 ± 218.75 | 518.3 ± 195.59 |
| Week 16, n=394, 392 | 536.4 ± 219.47 | 550.1 ± 221.77 |
| Week 24, n=392, 389 | 582.0 ± 232.93 | 580.8 ± 218.76 |
| Week 32, n=384, 375 | 606.5 ± 242.95 | 618.7 ± 237.56 |
| Week 40, n=371, 357 | 609.1 ± 239.11 | 623.1 ± 234.82 |
| Week 48, n=374, 357 | 623.8 ± 247.82 | 641.2 ± 241.75 |
| Week 60, n=367, 355 | 635.6 ± 241.27 | 648.5 ± 238.99 |
| Week 72, n=360, 350 | 635.2 ± 237.78 | 664.0 ± 239.86 |
| Week 84, n=351, 338 | 668.0 ± 246.50 | 677.5 ± 249.64 |
| Week 96, n=343, 328 | 679.8 ± 257.89 | 672.4 ± 237.54 |
Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline to a CDC CAT C event (EV); CDC CAT B at Baseline to a CDC CAT C EV; CDC CAT C at Baseline to a new CDC CAT C EV; or CDC CAT A, B, or C at Baseline to death.
| Participants | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Any category condition | 10 | 8 |
| Any Category B condition | 3 | 3 |
| Any Category C condition | 6 | 4 |
| Any death | 1 | 1 |
| Progression from CAT A to CAT C | 4 | 2 |
| Progression from CAT B to CAT C | 3 | 1 |
| Progression from CAT C to new CAT C | 0 | 1 |
| Progression from CAT A, B, or C to death | 1 | 1 |
All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Safety Population: all participants who received at least one dose of investigational product
| Participants | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| ALT | 57 | 70 |
| ALP | 7 | 15 |
| AST | 67 | 75 |
| CO2 content/bicarbonate | 58 | 67 |
| Cholesterol | 90 | 73 |
| CK | 61 | 47 |
| Creatinine | 11 | 7 |
| Hyperglycaemia | 70 | 87 |
| Hyperkalemia | 7 | 4 |
| Hypernatremia | 4 | 6 |
| Hypoglycaemia | 17 | 27 |
| Hypokalemia | 10 | 15 |
| Hyponatremia | 34 | 48 |
| LDL cholesterol calculation | 74 | 49 |
| Lipase | 55 | 62 |
| Phosphorus, inorganic | 65 | 71 |
| Total bilirubin | 27 | 24 |
| Triglycerides | 7 | 8 |
| Hemoglobin | 10 | 5 |
| Platelet count | 19 | 19 |
| Total neutrophils | 54 | 48 |
| White Blood Cell count | 19 | 7 |
AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. The predicted individual AUC(0-tau) were obtained from the final population PK model by an empirical Bayes estimation. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hours post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa. The Pharmacokinetic (PK) Concentration Population comprised of all participants who received DTG, had undergone PK sampling during the study, and provided evaluable DTG plasma concentration data.
| Micrograms*hour per milliliter(µg*hr/mL) | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau [AUC(0-tau)] of DTG | 53.6 ± 26.8 | — |
The maximum plasma concentration (Cmax) and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Week 48. The predicted individual Cmax and Ctau were obtained from the final population PK model by simulation of the concentration-time profiles. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hour post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa.
| Micrograms per milliliter (µg/mL) | DTG 50 mg Once a Day | RTG 400 mg BID |
|---|---|---|
| Cmax | 3.69 ± 19.6 | — |
| Ctau | 1.10 ± 46.5 | — |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the study (up to a median of 1267 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG 50 mg Once a Day | 1/411 (0.2%) | 41/411 (10%) | 353/411 (85.9%) |
| RTG 400mg BID | 1/411 (0.2%) | 45/411 (10.9%) | 344/411 (83.7%) |
| DTG 50 mg Once a Day (Open-label) | 0/338 (0%) | 21/338 (6.2%) | 256/338 (75.7%) |
| Event | DTG 50 mg Once a Day | RTG 400mg BID | DTG 50 mg Once a Day (Open-label) |
|---|---|---|---|
| AppendicitisInfections and infestations | 2/411 | 5/411 | 1/338 |
| Suicide attemptPsychiatric disorders | 2/411 | 3/411 | 1/338 |
| Drug hypersensitivityImmune system disorders | 3/411 | 0/411 | 1/338 |
| SyphilisInfections and infestations | 0/411 | 0/411 | 2/338 |
| PneumoniaInfections and infestations | 0/411 | 2/411 | 1/338 |
| LacerationInjury, poisoning and procedural complications | 0/411 | 2/411 | 0/338 |
| SeizureNervous system disorders | 0/411 | 2/411 | 0/338 |
| Suicidal ideationPsychiatric disorders | 0/411 | 2/411 | 0/338 |
| Anal abscessInfections and infestations | 0/411 | 1/411 | 1/338 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/411 | 0/411 | 1/338 |
| Event | DTG 50 mg Once a Day | RTG 400mg BID | DTG 50 mg Once a Day (Open-label) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 60/411 | 55/411 | 3/338 |
| DiarrhoeaGastrointestinal disorders | 58/411 | 54/411 | 21/338 |
| HeadacheNervous system disorders | 56/411 | 55/411 | 9/338 |
| Viral upper respiratory tract infectionInfections and infestations | 54/411 | 54/411 | 24/338 |
| Upper respiratory tract infectionInfections and infestations | 34/411 | 31/411 | 27/338 |
| SyphilisInfections and infestations | 24/411 | 28/411 | 24/338 |
| InsomniaPsychiatric disorders | 28/411 | 19/411 | 6/338 |
| Back painMusculoskeletal and connective tissue disorders | 24/411 | 26/411 | 10/338 |
| DepressionPsychiatric disorders | 26/411 | 18/411 | 8/338 |
| SinusitisInfections and infestations | 25/411 | 16/411 | 12/338 |
| Age, Continuous(Years) | DTG 50 mg Once a Day | RTG 400 mg BID | Total |
|---|---|---|---|
| Mean | 37.3 ± 9.19 | 36.6 ± 10.02 | 37.0 ± 9.61 |
| Sex: Female, Male(Participants) | DTG 50 mg Once a Day | RTG 400 mg BID | Total |
|---|---|---|---|
| Female | 63 | 56 | 119 |
| Male | 348 | 355 | 703 |
| Race/Ethnicity, Customized(Participants) | DTG 50 mg Once a Day | RTG 400 mg BID | Total |
|---|---|---|---|
| African American/African Heritage (Her) | 49 | 39 | 88 |
| American Indian or Alaska Native | 7 | 9 | 16 |
| Central/South Asian Her | 2 | 0 | 2 |
| Japanese/East Asian Her/South East Asian Her | 4 | 10 | 14 |
| Native Hawaiian or other Pacific Islander | 2 | 0 | 2 |
| White | 346 | 352 | 698 |
| African American/African Her and Asian and White | 1 | 0 | 1 |
| Asian and White | 0 | 1 | 1 |
Showing the first 100 of 101 sites across 9 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2010, a primary completion of Feb 2012 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 4 months after primary completion. A results delay was requested in Mar 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir